Daniel Wainstein
Président chez STELLA DIAGNOSTICS INC.
Fortune : 555 $ au 31/05/2024
Profil
Daniel Wainstein is currently the Chairman at Stella Diagnostics, Inc., Chairman at Chain Bridge I, and Owner at Seven Knots LLC.
Previously, he worked as the Chief Executive Officer at JMD Properties, Inc. and as a Director at Varian Biopharmaceuticals, Inc. He completed his undergraduate degree at Hofstra University in 2001 and his graduate degree at Maurice A.
Deane School of Law at Hofstra University in 2006.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
STELLA DIAGNOSTICS INC.
0,08% | 30/06/2022 | 7 030 ( 0,08% ) | 555 $ | 31/05/2024 |
Postes actifs de Daniel Wainstein
| Sociétés | Poste | Début |
|---|---|---|
| STELLA DIAGNOSTICS INC. | Président | - |
| CHAIN BRIDGE I | Président | 01/01/2024 |
| Seven Knots LLC | Corporate Officer/Principal | - |
Anciens postes connus de Daniel Wainstein
| Sociétés | Poste | Fin |
|---|---|---|
Varian Biopharmaceuticals, Inc.
 Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Directeur/Membre du Conseil | - |
JMD Properties, Inc.
 JMD Properties, Inc. Medical SpecialtiesHealth Technology JMD Properties, Inc. is a content conversion service provider, developer, and integrator for the 3D Stereo and auto-stereo media industry. Its services include proprietary 3D reality splitter 2D to 3D conversion; stereo and multi-view consulting and integration; value added reseller of turnkey multi-view systems for digital signage. The company was founded in 1989 and is headquartered in Cheyenne, WY. | Directeur Général | - |
Formation de Daniel Wainstein
| Hofstra University | Undergraduate Degree |
| Maurice A. Deane School of Law at Hofstra University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHAIN BRIDGE I | Finance |
| Entreprise privées | 4 |
|---|---|
| Stella Diagnostics, Inc. | |
JMD Properties, Inc.
JMD Properties, Inc. Medical SpecialtiesHealth Technology JMD Properties, Inc. is a content conversion service provider, developer, and integrator for the 3D Stereo and auto-stereo media industry. Its services include proprietary 3D reality splitter 2D to 3D conversion; stereo and multi-view consulting and integration; value added reseller of turnkey multi-view systems for digital signage. The company was founded in 1989 and is headquartered in Cheyenne, WY. | Health Technology |
| Seven Knots LLC | |
Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Health Technology |
